Please Wait

Applying Filters...

Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Fosaprepitant Dimeglumine

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 17 USDMF, 3 JDMF, 6 EU WC, 13 NDC API, 22 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

50 FDF Dossiers, 24 FDA Orange Book, 5 Europe, 1 Canada, 8 Australia, 3 South Africa, 9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 3 Actylis, 1 BASF, 1 DFE Pharma, 3 Gangwal Chemicals, 7 Kerry, 1 Microlex e.U, 1 Nanjing Bold Chemical, 6 Seppic

EXCIPIENTS BY APPLICATIONS

10 Solubilizers, 6 Parenteral, 5 Fillers, Diluents & Binders, 3 Topical, 3 Co-Processed Excipients, 3 Direct Compression, 3 Emulsifying Agents, 2 Film Formers & Plasticizers, 2 Surfactant & Foaming Agents, 2 Thickeners and Stabilizers, 1 Granulation, 1 Rheology Modifiers, 1 API Stability Enhancers

DIGITAL CONTENT

31 News #PharmaBuzz

31 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 3 Regulatory FDF Prices

MARKET PLACE

1 FDF Dossiers

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 2 US Exclusivities, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 Others

2 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/03/2025	Biophore India Pharmaceuticals Pvt Ltd	India	BIOPHORE INDIA PHARMACEUTICALS PVT LTD	40468	FOSAPREPITANT DIMEGLUMINE	2024-10-03	Active	II	N/A
28/03/2025	Dr. Reddy\'s Laboratories	India	DR REDDYS LABORATORIES LTD	38210	FOSAPREPITANT DIMEGLUMINE	2023-03-28	Active	II	Complete	2023-08-08	2023-07-05

Contact us
to update this info

Fosaprepitant Dimeglumine

Fosaprepitant Dimeglumine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers

17 USDMF

3 JDMF

6 EU WC

13 NDC API

22 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

50 FDF Dossiers

24 FDA Orange Book

5 Europe

1 Canada

8 Australia

3 South Africa

9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INTRAVENOUS - EQ 150MG BASE/VIAL

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical

3 Actylis

1 BASF

1 DFE Pharma

3 Gangwal Chemicals

7 Kerry

1 Microlex e.U

1 Nanjing Bold Chemical

6 Seppic

EXCIPIENTS BY APPLICATIONS

10 Solubilizers

6 Parenteral

5 Fillers, Diluents & Binders

3 Topical

3 Co-Processed Excipients

3 Direct Compression

3 Emulsifying Agents

2 Film Formers & Plasticizers

2 Surfactant & Foaming Agents

2 Thickeners and Stabilizers

1 Granulation

1 Rheology Modifiers

1 API Stability Enhancers

DIGITAL CONTENT

31 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

3 Regulatory FDF Prices

MARKET PLACE

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents

2 US Exclusivities

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 Others

Filters

POWDER;INTRAVENOUS - EQ 115MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons